Welcome to LookChem.com Sign In|Join Free
  • or
6-ethoxy-5-nitrosopyrimidine-2,4-diamine is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

6965-97-5

Post Buying Request

6965-97-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

6965-97-5 Usage

Chemical Type

Nitrosamine derivative

Mutagenic Potency

Potent mutagen

Applications

Pesticide Detection: Used as a reagent for detecting and quantifying pesticides in food and environmental samples.
Pharmaceutical Production: Employed in the synthesis of pharmaceuticals.
Agricultural Chemicals: Utilized in the manufacturing of agricultural chemicals.

Safety Concerns

Considered a potential carcinogen, so exposure should be minimized to prevent adverse health effects.

Check Digit Verification of cas no

The CAS Registry Mumber 6965-97-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,9,6 and 5 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 6965-97:
(6*6)+(5*9)+(4*6)+(3*5)+(2*9)+(1*7)=145
145 % 10 = 5
So 6965-97-5 is a valid CAS Registry Number.

6965-97-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name 6-ethoxy-5-nitrosopyrimidine-2,4-diamine

1.2 Other means of identification

Product number -
Other names 5-nitroso-2,6-diamino-4-ethoxy-pyrimidine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:6965-97-5 SDS

6965-97-5Downstream Products

6965-97-5Relevant academic research and scientific papers

Imidazopyridine- and purine-thioacetamide derivatives: Potent inhibitors of nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1)

Chang, Lei,Lee, Sang-Yong,Leonczak, Piotr,Rozenski, Jef,De Jonghe, Steven,Hanck, Theodor,Müller, Christa E.,Herdewijn, Piet

, p. 10080 - 10100 (2015/02/05)

Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) belongs to the family of ecto-nucleotidases, which control extracellular nucleotide, nucleoside, and (di)phosphate levels. To study the (patho)physiological roles of NPP1 potent and selective inhibitors with drug-like properties are required. Therefore, a compound library was screened for NPP1 inhibitors using a colorimetric assay with p-nitrophenyl 5′-thymidine monophosphate (p-Nph-5′-TMP) as an artificial substrate. This led to the discovery of 2-(3H-imidazo[4,5-b]pyridin-2-ylthio)-N-(3,4-dimethoxyphenyl)acetamide (5a) as a hit compound with a Ki value of 217 nM. Subsequent structure-activity relationship studies led to the development of purine and imidazo[4,5-b]pyridine analogues with high inhibitory potency (Ki values of 5.00 nM and 29.6 nM, respectively) when assayed with p-Nph-5′-TMP as a substrate. Surprisingly, the compounds were significantly less potent when tested versus ATP as a substrate, with Ki values in the low micromolar range. A prototypic inhibitor was investigated for its mechanism of inhibition and found to be competitive versus both substrates.

Synthesis and in vitro evaluation of 2-amino-4-N-piperazinyl-6-(3,4- dimethoxyphenyl)-pteridines as dual immunosuppressive and anti-inflammatory agents

De Jonghe, Steven,Marchand, Arnaud,Gao, Ling-Jie,Calleja, Agnes,Cuveliers, Eva,Sienaert, Ilse,Herman, Jean,Clydesdale, Gavin,Sefrioui, Hassane,Lin, Yuan,Pfleiderer, Wolfgang,Waer, Mark,Herdewijn, Piet

scheme or table, p. 145 - 149 (2011/02/25)

Screening of a pteridine-based compound library led to the identification of compounds exhibiting immunosuppressive as well as anti-inflammatory activity. Optimization afforded a series of 2-amino-4-N-piperazinyl-6-(3,4- dimethoxyphenyl)pteridine analogues. The most potent congeners in this series displayed low nM IC50 values in the Mixed Lymphocyte Reaction (MLR) assay. In addition, these compounds also have potent anti-inflammatory activity as measured in the Tumor Necrosis Factor (TNF) assay.

Synthesis and biological evaluation of 5-substituted O4- alkylpyrimidines as CDK2 inhibitors

Marchetti, Francesco,Cano, Celine,Curtin, Nicola J.,Golding, Bernard T.,Griffin, Roger J.,Haggerty, Karen,Newell, David R.,Parsons, Rachel J.,Payne, Sara L.,Wang, Lan Z.,Hardcastle, Ian R.

supporting information; experimental part, p. 2397 - 2407 (2010/07/09)

CDK2 inhibitory structure-activity relationships have been explored for a range of 5-substituted O4-alkylpyrimidines. Variation of the 5-substituent in the 2,6-diaminopyrimidine series confirmed the 5-nitroso substituent as optimal, and showed that 5-formyl and 5-acetyl substituents were also tolerated at this position. A series of O4-alkyl-N 2-aryl-5-substituted-6-aminopyrimidines revealed interesting structure-activity relationships. In the 5-nitroso series, the optimum O 4-alkyl substituents were cyclohexylmethyl or sec-butyl, combined with a 2-sulfanilyl group. By contrast, in the N2-arylsulfonamido-5- formyl series, the cyclohexylmethyl compound showed relatively poor activity compared with the sec-butyl derivative (22j, (R)-4-(4-amino-6-sec-butoxy-5- formylpyrimidin-2-ylamino)benzenesulfonamide; CDK2 IC50 = 0.8 nM). Similarly, in the N2-arylsulfonamido-5-(hydroxyiminomethyl) series the O4-sec-butyl substituent conferred greater potency than the cyclohexylmethyl (23c, (rac)-4-(4-amino-6-sec-butoxy-5-(hydroxyiminomethyl) pyrimidin-2-ylamino)benzenesulfonamide; CDK2 IC50 = 7.4 nM). The 5-formyl derivatives show selectivity for CDK2 over other CDK family members, and are growth inhibitory in tumour cells (e.g.22j, GI50 = 0.57 μM).

Immunosuppressive effects of pteridine derivatives

-

Page 23, (2008/06/13)

This invention relates to a group of trisubstituted and tetrasubstituted pteridine derivatives, their pharmaceutically acceptable salts, N-oxides, solvates, dihydro- and tetrahydroderivatives and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular which are highly active immunosuppressive agents, and as such are useful in the treatment in transplant rejection and/or in the treatment of certain inflammatory diseases. These compounds are also useful in preventing or treating cardiovascular disorders, allergic conditions, disorders of the central nervous system and cell proliferative disorders.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 6965-97-5